FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and older

US health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic.

Moderna is seeking Food and Drug Administration (FDA) approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season.